Chapter 25. Chemoprevention of Prostate Cancer

  1. Philipp Dahm MD, MHSc, FACS Associate Professor of Urology Director of Clinical Research3 and
  2. Roger R. Dmochowski MD Professor Director of Female Pelvic Medicine and Reconstruction4
  1. Amanda Beth Reed1,
  2. Kristin C. Reed2 and
  3. Dipen J. Parekh1

Published Online: 9 JUL 2010

DOI: 10.1002/9781444323146.ch25

Evidence-Based Urology

Evidence-Based Urology

How to Cite

Beth Reed, A., Reed, K. C. and Parekh, D. J. (2010) Chemoprevention of Prostate Cancer, in Evidence-Based Urology (eds P. Dahm and R. R. Dmochowski), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444323146.ch25

Editor Information

  1. 3

    Department of Urology, University of Florida, Gainesville, FL, USA

  2. 4

    Department of Urologic Surgery, Vanderbilt University, Nashville, TN, USA

Author Information

  1. 1

    Department of Urology, University of Texas, Health Sciences Center at San Antonio, San Antonio, TX, USA

  2. 2

    South Texas Veterans Health Care System, San Antonio, TX, USA

Publication History

  1. Published Online: 9 JUL 2010
  2. Published Print: 25 JUN 2010

ISBN Information

Print ISBN: 9781405185943

Online ISBN: 9781444323146



  • Chemoprevention;
  • prostate cancer;
  • 5-alpha reductase inhibitor;
  • finasteride;
  • selenium;
  • vitamin E


Purpose of Review

We examine the role of chemotherapeutic agents in the prevention of prostate cancer and analyze the phase III clinical trials investigating the application of these agents for prostate cancer

Recent Findings

There are two reported phase III randomized clinical trials which evaluate the role of chemotherapeutic agents in the prevention of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) originally revealed that finasteride reduced the risk of prostate cancer by approximately 25% versus placebo but patients who received finasteride had a greater incidence of high grade tumors. Recent updates of the PCPT confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to improvement the performance characteristics of PSA and prostate biopsy to improve cancer detection. The SELECT trial evaluated the roles of selenium and vitamin E in the prevention of prostate cancer, but found no benefit of either supplement


Chemoprevention of prostate cancer is now possible with finasteride. An ancillary benefit includes an enhancement in detection of high grade, potentially fatal, prostate cancer